SCHEMBL5753755

SCHEMBL5753755

O=C1CC2CCCN2C(=O)N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
BRCA1 P38398 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 4/20 0.38
GAA P10253 2/20 0.38
NOS1 P29475 2/20 0.36
NOS3 P29474 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.34
MAPK1 P28482 1/20 0.33
CRBN Q96SW2 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25343411 1.00 MAPT (0.38) MAPTKMT2AMEN1BRCA1ATM
SCHEMBL31436247 1.00 MAPT (0.38) MAPTKMT2AMEN1BRCA1ATM
SCHEMBL31436228 0.94 MAPT (0.44) MAPTKMT2AMEN1BRCA1ATM
SCHEMBL10761357 0.94 MAPT (0.44) MAPTKMT2AMEN1BRCA1ATM
Oxalic Acid SCHEMBL31533523 0.93 PLA2G7 (0.37) MAPTKMT2AMEN1BRCA1ATM
SCHEMBL17748861 0.75 GAA (0.64) MAPTKMT2AMEN1KDM4EALDH1A1
SCHEMBL2512781 0.74 ALDH1A1 (0.42) MAPTKMT2AMEN1BRCA1ATM
SCHEMBL19370610 0.73 OPRM1 (0.40) MAPTKDM4EALDH1A1GAANOS1
SCHEMBL9188344 0.73
SCHEMBL9188342 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463455-B1 HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS SUVEN LIFE SCIENCES LTD (IN) 2026-04-29 EP claimed
US-12391698-B2 Substituted piperidines and piperazines and methods for the treatment of CNS disorders SUVEN LIFE SCIENCES LIMITED (IN) 2025-08-19 US disclosed
US-20250092049-A1 HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS SUVEN LIFE SCIENCES LIMITED (IN) 2025-03-20 US disclosed
EP-1244670-B1 HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME MGI GP INC (US) 2006-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391698-B2 Substituted piperidines and piperazines and methods for the treatment of CNS disorders GRIN2C, SLC1A2, CNR2 MAPT 725/4885KMT2A 1230/4885MEN1 1883/4885
US-20250092049-A1 HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS GRIN2C, CNR2, INA MAPT 219/4885KMT2A 1988/4885MEN1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.